The FDA approved Paratek’s supplemental New Drug Application (sNDA) for the oral-only dosing regimen of NUZYRA® for the treatment of adults with Community-Acquired Bacterial Pneumonia (CABP)
Always Be a Step Ahead
Learn the important healthcare trends that could affect you in advance. Get expert analysis and discover the innovative ideas that are helping businesses overcome today's challenges.
Subscribe to AMI's Insights Newsletter Today.
